Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

ASCO 2024: Lung Cancer’s 10+ interesting data readouts to look forward

Home
asco conference 2024
lung cancer 10 plus data readouts

Lung Cancer’s 10+ Data Readouts | ASCO 2024

NSCLC, a significant malignancy affecting populations in the US and major European nations, is at the forefront as ASCO 2024 approaches. Top pharmaceutical companies such as AstraZeneca, AbbVie, Gilead Sciences, Dizal Pharma, Amgen, Daiichi Sankyo, and others are gearing up for the conference, ready to present data and final analyses. Below listed abstracts informs about the expected data readouts of existing and novel set of targets including Astrazeneca’s EGFR inhibitors, Gilead’s TROP-2 targeting ADC, Summit therapeutics’ PD-1/VEGF bi-specific antibody, Betta Pharma’s EGFR/c-MET bispecific antibody, Lilly’s 2nd generation KRASG12C inhibitor, Hansoh Bio’s B7-H3 ADC along with many other interesting posters and oral presentations. Additionally, updated findings from the LUMINOSITY trial, with a focus on c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC, along with primary results from the Phase III EVOKE-01 study are eagerly awaited.

On this note, DelveInsight has compiled a list of the top abstracts including both NSCLC and SCLC, poised to potentially revolutionize patient care in the near future.

NSCLC Key Abstracts

Company	Drug	Trial ID / Acronym	Phase	Abstract ID	Abstract Title
	Sacituzumab govitecan	NCT05089734/ EVOKE-01	III	Oral Abstract Session - LBA8500	Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study
	Osimertinib	NCT03521154/ LAURA	III	Plenary Session - LBA4	Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
	Amivantamab	NCT05388669/ PALOMA-3	III	Oral Abstract Session - LBA8505	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial
	Ivonescimab	NCT05184712/ HARMONi	III	Oral Abstract Session - 8508	Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial
	Sacituzumab tirumotecan	NCT05351788/ OptiTROP-Lung01	II	Oral Abstract Session - 8502	Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study
$C:\Users\Himanshu Saxena\AppData\Local\Packages\Microsoft.Windows.Photos_8wekyb3d8bbwe\TempState\ShareServiceTempFolder\download.jpeg$	Telisotuzumab vedotin	NCT03539536/ LUMINOSITY	II	Clinical Science Symposium - 103	Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial
	Acasunlimab	NCT05117242	II	Poster Session - 12, Abstract- 2533	Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial
	Amivantamab	NCT05498428/ PALOMA-2	II	Poster Session - 476, Abstract- LBA8612	Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study
	Sunvozertinib	NCT03974022/ WU-KONG1	I/II	Rapid Oral Abstract Session - 8513	A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study
	MCLA-129	NCT04930432	I/II	Poster Session - 468, Abstract- 8604	Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
	Olomorasib (LY3537982)	NCT04956640	I/II	Clinical Science Symposium - 8510	Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
	Sigvotatug vedotin	NCT04389632	I	Rapid Oral Abstract Session - 8521	Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001)
	HS-20093	NCT05276609/ ARTEMIS-001	I	Poster Session - 355, Abstract- 8093	ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC)